Impact of high-flux vs. conventional hemodialysis on clinical efficacy in patients with chronic renal failure (uremic stage) using real-world data.

OBJECTIVE

Based on real-world data, this retrospective investigation discusses the impact of high-flux hemodialysis (HFHD) versus conventional hemodialysis (HD) on clinical outcomes in patients with chronic renal failure (CRF) of the uremic stage.

METHODS

We selected 192 CRF (uremic stage) cases and conducted grouping based on intervention schemes: the HFHD group (n=100) received HFHD, while the HD group (n=92) received HD. We then conducted comparative analyses between the groups, with the dimensions covering: clinical efficacy; dialysis adequacy; toxin clearance efficiency; complications; inflammation; nutrition; bone metabolism (serum calcium [Ca], serum phosphorus [P], intact parathyroid hormone [iPTH]); and all-cause mortality.

RESULTS

HFHD was associated with markedly higher therapeutic efficacy than HD. While demonstrating a dialysis adequacy equivalent to that of HD group, HFHD showed superior toxin clearance efficiency, induced fewer complications, and led to markedly lower one-year all-cause mortality rates. In addition, the post-interventional inflammatory markers, P, and iPTH of HFHD group displayed greater reductions compared to the control group, along with more pronounced increases in nutritional indices and Ca.

CONCLUSION

HFHD outperforms conventional HD in clinical efficacy in managing uremic-stage CRF patients.